Medpace Holdings (01P) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

01P Analyst Ratings

Hold

2 Buy

9 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Medpace

Holdings

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

01P Stock 12 Month Forecast

Average Price Target

€510.02

▼(-0.77% Downside)

Based on 11 Wall Street analysts offering 12 month price targets for Medpace Holdings in the last 3 months. The average price target is €510.02 with a high forecast of €608.30 and a low forecast of €395.57. The average price target represents a -0.77% change from the last price of €514.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"270":"€270","609":"€609","354.75":"€354.8","439.5":"€439.5","524.25":"€524.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":608.29603292,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€608.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":510.01930390199993,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€510.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":395.5682295,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€395.57</span>\n  </div></div>","useHTML":true}}],"tickPositions":[270,354.75,439.5,524.25,609],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,484.1,493.65354099384615,503.20708198769233,512.7606229815385,522.3141639753846,531.8677049692308,541.4212459630769,550.9747869569231,560.5283279507693,570.0818689446154,579.6354099384615,589.1889509323078,598.7424919261539,{"y":608.29603292,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,484.1,486.0937926078462,488.08758521569234,490.08137782353845,492.0751704313846,494.06896303923077,496.0627556470769,498.05654825492303,500.0503408627692,502.04413347061535,504.0379260784615,506.0317186863076,508.0255112941538,{"y":510.01930390199993,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,484.1,477.2898638076923,470.4797276153846,463.66959142307695,456.85945523076924,450.04931903846153,443.2391828461538,436.42904665384617,429.61891046153846,422.80877426923075,415.99863807692304,409.18850188461533,402.3783656923077,{"y":395.5682295,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":271.3,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":363.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":403.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":461.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":506,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":505.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":480.7,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":495.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":390.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":421.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":355.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":386.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 69,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":484.1,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 87,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€608.30

Average Price Target€510.02

Lowest Price Target€395.57

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ann Hynes

Mizuho Securities

€584.56

Buy

13.73%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Medpace Holdings (NASDAQ: MEDP), NeuroPace (NASDAQ: NPCE) and Cardinal Health (NYSE: CAH)

Jailendra Singh

Truist Financial

€535.34

Hold

4.15%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Molina Healthcare (NYSE: MOH) and Medpace Holdings (NASDAQ: MEDP)

Sean Dodge

BMO Capital

€527.42

Hold

2.61%

Upside

Reiterated

07/27/26

Wall Street Analysts Are Neutral on Top Healthcare Picks

Eric Coldwell

Robert W. Baird

€480.84→€548.52

Hold

6.72%

Upside

Reiterated

07/24/26

Medpace price target raised to $624 from $547 at BairdMedpace price target raised to $624 from $547 at Baird

Charles Rhyee

TD Cowen

€368.32→€432.49

Hold

-15.86%

Downside

Assigned

07/23/26

Charles Rhyee Maintains Hold Rating, Raises Price Target to $492 Amid Near-Term Strength and 2027 Metabolic Concentration Risks

Jared Haase

William Blair

―

Hold

―

Reiterated

07/23/26

Medpace Rally and Record Bookings Prompt Valuation Caution as Haase Reiterates Hold Rating

Michael Cherny

Leerink Partners

€452.71→€545.01

Hold

6.03%

Upside

Reiterated

07/23/26

Medpace price target raised to $620 from $515 at LeerinkMedpace price target raised to $620 from $515 at Leerink

Luke Sergott

Barclays

€395.57

Hold

-23.04%

Downside

Reiterated

07/23/26

Barclays Reaffirms Their Hold Rating on Medpace Holdings (MEDP)

Ryan Halsted

RBC Capital

€425.46→€608.3

Buy

18.35%

Upside

Reiterated

07/23/26

RBC Capital Sticks to Their Buy Rating for Medpace Holdings (MEDP)

Justin Bowers

Deutsche Bank

€421.94→€470.29

Hold

-8.50%

Downside

Reiterated

07/23/26

Medpace price target raised to $535 from $480 at Deutsche BankMedpace price target raised to $535 from $480 at Deutsche Bank

David Windley

Jefferies

€430.73→€452.71

Hold

-11.92%

Downside

Downgraded

07/07/26

Medpace downgraded to Hold from Buy at JefferiesMedpace downgraded to Hold from Buy at Jefferies

Jamie Clark

Rothschild & Co Redburn

€300.63→€416.67

Hold

-18.94%

Downside

Downgraded

09/03/25

Redburn Atlantic downgrades Medpace Holdings (MEDP) to a Hold

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ann Hynes

Mizuho Securities

€584.56

Buy

13.73%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Medpace Holdings (NASDAQ: MEDP), NeuroPace (NASDAQ: NPCE) and Cardinal Health (NYSE: CAH)

Jailendra Singh

Truist Financial

€535.34

Hold

4.15%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Molina Healthcare (NYSE: MOH) and Medpace Holdings (NASDAQ: MEDP)

Sean Dodge

BMO Capital

€527.42

Hold

2.61%

Upside

Reiterated

07/27/26

Wall Street Analysts Are Neutral on Top Healthcare Picks

Eric Coldwell

Robert W. Baird

€480.84→€548.52

Hold

6.72%

Upside

Reiterated

07/24/26

Medpace price target raised to $624 from $547 at BairdMedpace price target raised to $624 from $547 at Baird

Charles Rhyee

TD Cowen

€368.32→€432.49

Hold

-15.86%

Downside

Assigned

07/23/26

Charles Rhyee Maintains Hold Rating, Raises Price Target to $492 Amid Near-Term Strength and 2027 Metabolic Concentration Risks

Jared Haase

William Blair

―

Hold

―

Reiterated

07/23/26

Medpace Rally and Record Bookings Prompt Valuation Caution as Haase Reiterates Hold Rating

Michael Cherny

Leerink Partners

€452.71→€545.01

Hold

6.03%

Upside

Reiterated

07/23/26

Medpace price target raised to $620 from $515 at LeerinkMedpace price target raised to $620 from $515 at Leerink

Luke Sergott

Barclays

€395.57

Hold

-23.04%

Downside

Reiterated

07/23/26

Barclays Reaffirms Their Hold Rating on Medpace Holdings (MEDP)

Ryan Halsted

RBC Capital

€425.46→€608.3

Buy

18.35%

Upside

Reiterated

07/23/26

RBC Capital Sticks to Their Buy Rating for Medpace Holdings (MEDP)

Justin Bowers

Deutsche Bank

€421.94→€470.29

Hold

-8.50%

Downside

Reiterated

07/23/26

Medpace price target raised to $535 from $480 at Deutsche BankMedpace price target raised to $535 from $480 at Deutsche Bank

David Windley

Jefferies

€430.73→€452.71

Hold

-11.92%

Downside

Downgraded

07/07/26

Medpace downgraded to Hold from Buy at JefferiesMedpace downgraded to Hold from Buy at Jefferies

Jamie Clark

Rothschild & Co Redburn

€300.63→€416.67

Hold

-18.94%

Downside

Downgraded

09/03/25

Redburn Atlantic downgrades Medpace Holdings (MEDP) to a Hold

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medpace Holdings

3 Months

Ann HynesMizuho Securities

Success Rate

5/11 ratings generated profit

Average Return

+6.03%

reiterated a buy rating 7 days ago

Copying Ann Hynes's trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +6.03% per trade.

1 Year

Ann HynesMizuho Securities

Success Rate

9/11 ratings generated profit

Average Return

+24.62%

reiterated a buy rating 7 days ago

Copying Ann Hynes's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +24.62% per trade.

2 Years

Ann HynesMizuho Securities

Success Rate

10/11 ratings generated profit

Average Return

+35.89%

reiterated a buy rating 7 days ago

Copying Ann Hynes's trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +35.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

01P Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

116

108

106

114

In the current month, 01P has received 87 Buy Ratings, 27 Hold Ratings, and 0 Sell Ratings. 01P average Analyst price target in the past 3 months is 510.02.

Each month's total comprises the sum of three months' worth of ratings.

01P Financial Forecast

01P Earnings Forecast

Next quarter’s earnings estimate for 01P is €3.85 with a range of €3.77 to €4.05. The previous quarter’s EPS was €3.71. 01P beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.85% of the time in the same period. In the last calendar year 01P has Outperformed its overall industry.

01P Sales Forecast

Next quarter’s sales forecast for 01P is €623.60M with a range of €616.47M to €642.55M. The previous quarter’s sales results were €617.55M. 01P beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 49.36% of the time in the same period. In the last calendar year 01P has Outperformed its overall industry.

01P Stock Forecast FAQ

What is DE:01P’s average 12-month price target, according to analysts?

Based on analyst ratings, Medpace Holdings’s 12-month average price target is 510.02.

What is DE:01P’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:01P, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Medpace Holdings a Buy, Sell or Hold?

Medpace Holdings has a consensus rating of Hold, which is based on 2 buy ratings, 9 hold ratings and 0 sell ratings.

What is Medpace Holdings’s share price target?

The average share price target for Medpace Holdings is 510.02. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €608.30 ,and the lowest forecast is €395.57. The average share price target represents -0.77% Decrease from the current price of €514.

What do analysts say about Medpace Holdings?

Medpace Holdings’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Medpace Holdings?

To buy shares of DE:01P, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Medpace Holdings (01P) Stock Forecast & Price Target

01P Analyst Ratings

01P Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Medpace Holdings

01P Analyst Recommendation Trends

01P Financial Forecast

01P Earnings Forecast

01P Sales Forecast

01P Stock Forecast FAQ

Detailed List of Analyst Forecasts